Pulmonary Manifestations of Sarcoidosis



Sarcoidosis is a multisystem disease that can cause a myriad of symptoms and clinical abnormalities. While sarcoidosis has been recognized in the modern medical literature for nearly 150 years, the cause of sarcoidosis is still unknown and the diagnosis remains one of exclusion. More than half of sarcoidosis patients have at least two organs involved, implying that diagnosis and management require a multidisciplinary approach. The prognosis of sarcoidosis is good for the majority of patients, but it is difficult to predict which ones will remit spontaneously at the outset of the disease. It does not appear that early treatment substantially influences the likelihood of spontaneous remission. Therefore, the indications for treatment fall broadly into the two categories of threats to organ function and significant impairment of the quality of life. A range of associated manifestations, such as pulmonary hypertension, mycetomas, upper airways involvement, and sleep apnea, may complicate the management of sarcoidosis.


Pulmonary Hypertension Idiopathic Pulmonary Fibrosis Granulomatous Inflammation Cardiac Sarcoidosis Hypersensitivity Pneumonitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    James DG. Descriptive definition and historic aspects of sarcoidosis. Clin Chest Med. 1997;18: 663–79.PubMedCrossRefGoogle Scholar
  2. 2.
    Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other granulomatous disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:149–73.PubMedGoogle Scholar
  3. 3.
    Bresnitz EA, Strom BL. Epidemiology of sarcoidosis. Epidemiol Rev. 1983;5:124–56.PubMedGoogle Scholar
  4. 4.
    Mayock RL, Bertrand P, Morrison CE, et al. Manifestations of sarcoidosis. Analysis of 145 patients, with a review of nine series selected from the literature. Am J Med. 1963;35:67–89.PubMedCrossRefGoogle Scholar
  5. 5.
    Edmondstone WM, Wilson AG. Sarcoidosis in Caucasians, Blacks and Asians in London. Br J Dis Chest. 1985;79:27–36.PubMedCrossRefGoogle Scholar
  6. 6.
    Siltzbach LE, James DG, Neville E, et al. Course and prognosis of sarcoidosis around the world. Am J Med. 1974;57:847–52.PubMedCrossRefGoogle Scholar
  7. 7.
    Rybicki BA, Major M, Popovich Jr J, et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145:234–41.PubMedCrossRefGoogle Scholar
  8. 8.
    Keller AZ. Hospital, age, racial, occupational, geographical, clinical and survivorship characteristics in the epidemiology of sarcoidosis. Am J Epidemiol. 1971;94:222–30.PubMedGoogle Scholar
  9. 9.
    McNicol MW, Luce PJ. Sarcoidosis in a racially mixed community. J R Coll Physicians Lond. 1985;19:179–83.PubMedGoogle Scholar
  10. 10.
    Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164:1885–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Gideon NM, Mannino DM. Sarcoidosis mortality in the United States 1979–1991: an analysis of multiple-cause mortality data. Am J Med. 1996;100: 423–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Hosoda Y, Yamaguchi M, Hiraga Y. Global epidemiology of sarcoidosis. What story do prevalence and incidence tell us? Clin Chest Med. 1997;18:681–94.PubMedCrossRefGoogle Scholar
  13. 13.
    Reid JD. Sarcoidosis in coroner’s autopsies: a critical evaluation of diagnosis and prevalence from Cuyahoga County, Ohio. Sarcoidosis Vasc Diffuse Lung Dis. 1998;15:44–51.PubMedGoogle Scholar
  14. 14.
    Henke CE, Henke G, Elveback LR, et al. The epidemiology of sarcoidosis in Rochester, Minnesota: a population-based study of incidence and survival. Am J Epidemiol. 1986;123:840–5.PubMedGoogle Scholar
  15. 15.
    Milman N, Selroos O. Pulmonary sarcoidosis in the Nordic countries 1950–1982. II. Course and prognosis. Sarcoidosis. 1990;7:113–8.PubMedGoogle Scholar
  16. 16.
    Hillerdal G, Nou E, Osterman K, et al. Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am Rev Respir Dis. 1984;130:29–32.PubMedGoogle Scholar
  17. 17.
    Cozier YC, Berman JS, Palmer JR, et al. Sarcoidosis in black women in the United States: data from the Black Women’s Health Study. Chest. 2011;139: 144–50.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    James DG. Epidemiology of sarcoidosis. Sarcoidosis. 1992;9:79–87.PubMedGoogle Scholar
  19. 19.
    Culver DA, Thomassen MJ, Kavuru MS. Pulmonary sarcoidosis: new genetic clues and ongoing treatment controversies. Cleve Clin J Med. 2004;71:88. 90, 92 passim.PubMedCrossRefGoogle Scholar
  20. 20.
    Culver DA, Newman LS, Kavuru MS. Gene-environment interactions in sarcoidosis: challenge and opportunity. Clin Dermatol. 2007;25:267–75.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Newman KL, Newman LS. Occupational causes of sarcoidosis. Curr Opin Allergy Clin Immunol. 2012;12:145–50.PubMedCrossRefGoogle Scholar
  22. 22.
    Gentry JT, Nitowsky HM, Michael Jr M. Studies on the epidemiology of sarcoidosis in the United States: the relationship to soil areas and to urban–rural residence. J Clin Invest. 1955;34:1839–56.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Newman LS, Rose CS, Bresnitz EA, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170:1324–30.PubMedCrossRefGoogle Scholar
  24. 24.
    Rybicki BA, Amend KL, Maliarik MJ, et al. Photocopier exposure and risk of sarcoidosis in African-American sibs. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21:49–55.PubMedGoogle Scholar
  25. 25.
    Kajdasz DK, Lackland DT, Mohr LC, et al. A current assessment of rurally linked exposures as potential risk factors for sarcoidosis. Ann Epidemiol. 2001;11: 111–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Song Z, Marzilli L, Greenlee BM, et al. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med. 2005;201:755–67.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Oswald-Richter KA, Culver DA, Hawkins C, et al. Cellular responses to mycobacterial antigens are present in bronchoalveolar lavage fluid used in the diagnosis of sarcoidosis. Infect Immun. 2009;77: 3740–8.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Chen ES, Wahlstrom J, Song Z, et al. T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis. J Immunol. 2008;181:8784–96.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Drake W, Richmond BW, Oswald-Richter K, et al. Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30:201–11.PubMedCentralPubMedGoogle Scholar
  30. 30.
    Drake WP, Oswald-Richter K, Richmond BW, et al. Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. JAMA Dermatol. 2013;149:1040–9.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Chen ES, Song Z, Willett MH, et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med. 2010;181:360–73.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Eishi Y. Etiologic link between sarcoidosis and Propionibacterium acnes. Respir Investig. 2013;51:56–68.PubMedCrossRefGoogle Scholar
  33. 33.
    Oswald-Richter KA, Beachboard DC, Seeley EH, et al. Dual analysis for mycobacteria and propionibacteria in sarcoidosis BAL. J Clin Immunol. 2012;32:1129–40.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Culver DA. What is sarcoidosis? Respir Med. 2013;107:1285–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Grunewald J. Review: role of genetics in susceptibility and outcome of sarcoidosis. Semin Respir Crit Care Med. 2010;31:380–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Sverrild A, Backer V, Kyvik KO, et al. Heredity in sarcoidosis: a registry-based twin study. Thorax. 2008;63:894–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Rybicki BA, Iannuzzi MC, Frederick MM, et al. Familial aggregation of sarcoidosis. A case–control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med. 2001;164:2085–91.PubMedCrossRefGoogle Scholar
  38. 38.
    McGrath DS, Daniil Z, Foley P, et al. Epidemiology of familial sarcoidosis in the UK. Thorax. 2000;55:751–4.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Rossman MD, Thompson B, Frederick M, et al. HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet. 2003;73:720–35.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Spagnolo P, Grunewald J. Recent advances in the genetics of sarcoidosis. J Med Genet. 2013;50:290–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Culver DA, Costabel U. EBUS-TBNA for the diagnosis of sarcoidosis: is it the only game in town? J Bronchology Interv Pulmonol. 2013;20:195–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2011;183:573–81.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Grunewald J, Eklund A. Sex-specific manifestations of Lofgren’s syndrome. Am J Respir Crit Care Med. 2007;175:40–4.PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    Highland KB, Retalis P, Coppage L, et al. Is there an anatomic explanation for chest pain in patients with pulmonary sarcoidosis? South Med J. 1997;90:911–4.PubMedCrossRefGoogle Scholar
  45. 45.
    Judson MA, Thompson BW, Rabin DL, et al. The diagnostic pathway to sarcoidosis. Chest. 2003;123:406–12.PubMedCrossRefGoogle Scholar
  46. 46.
    Sweiss NJ, Patterson K, Sawaqed R, et al. Rheumatologic manifestations of sarcoidosis. Semin Respir Crit Care Med. 2010;31:463–73.PubMedCentralPubMedCrossRefGoogle Scholar
  47. 47.
    Yanardag H, Caner M, Papila I, et al. Diagnostic value of peripheral lymph node biopsy in sarcoidosis: a report of 67 cases. Can Respir J. 2007;14:209–11.PubMedCentralPubMedGoogle Scholar
  48. 48.
    Culver DA. Sarcoidosis. Immunol Allergy Clin North Am. 2012;32:487–511.PubMedCrossRefGoogle Scholar
  49. 49.
    Fireman E, Haimsky E, Noiderfer M, et al. Misdiagnosis of sarcoidosis in patients with chronic beryllium disease. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:144–8.PubMedGoogle Scholar
  50. 50.
    Studdy PR, Lapworth R, Bird R. Angiotensin-converting enzyme and its clinical significance—a review. J Clin Pathol. 1983;36:938–47.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Lieberman J, Nosal A, Schlessner A, et al. Serum angiotensin-converting enzyme for diagnosis and therapeutic evaluation of sarcoidosis. Am Rev Respir Dis. 1979;120:329–35.PubMedGoogle Scholar
  52. 52.
    Borowsky SA, Lieberman J, Strome S, et al. Elevation of serum angiotensin—converting enzyme level. Occurrence in alcoholic liver disease. Arch Intern Med. 1982;142:893–5.PubMedCrossRefGoogle Scholar
  53. 53.
    Ainslie GM, Benatar SR. Serum angiotensin converting enzyme in sarcoidosis: sensitivity and specificity in diagnosis: correlations with disease activity, duration, extra-thoracic involvement, radiographic type and therapy. Q J Med. 1985;55:253–70.PubMedGoogle Scholar
  54. 54.
    Biller H, Zissel G, Ruprecht B, et al. Genotype-corrected reference values for serum angiotensin-converting enzyme. Eur Respir J. 2006;28:1085–90.PubMedCrossRefGoogle Scholar
  55. 55.
    Bargagli E, Bennett D, Maggiorelli C, et al. Human chitotriosidase: a sensitive biomarker of sarcoidosis. J Clin Immunol. 2013;33:264–70.PubMedCrossRefGoogle Scholar
  56. 56.
    Bargagli E, Bianchi N, Margollicci M, et al. Chitotriosidase and soluble IL-2 receptor: comparison of two markers of sarcoidosis severity. Scand J Clin Lab Invest. 2008;68:479–83.PubMedCrossRefGoogle Scholar
  57. 57.
    Rothkrantz-Kos S, van Dieijen-Visser MP, Mulder PG, et al. Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem. 2003;49:1510–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Studdy PR, Bird R, Neville E, et al. Biochemical findings in sarcoidosis. J Clin Pathol. 1980;33: 528–33.PubMedCentralPubMedCrossRefGoogle Scholar
  59. 59.
    Hedfors E, Holm G, Pettersson D. Lymphocyte subpopulations in sarcoidosis. Clin Exp Immunol. 1974;17:219–26.PubMedCentralPubMedGoogle Scholar
  60. 60.
    Winterbauer RH, Belic N, Moores KD. Clinical interpretation of bilateral hilar adenopathy. Ann Intern Med. 1973;78:65–71.PubMedCrossRefGoogle Scholar
  61. 61.
    Reich JM, Brouns MC, O’Connor EA, et al. Mediastinoscopy in patients with presumptive stage I sarcoidosis: a risk/benefit, cost/benefit analysis. Chest. 1998;113:147–53.PubMedCrossRefGoogle Scholar
  62. 62.
    Teirstein AS, Machac J, Almeida O, et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest. 2007;132:1949–53.PubMedCrossRefGoogle Scholar
  63. 63.
    Keijsers RG, Grutters JC, Thomeer M, et al. Imaging the inflammatory activity of sarcoidosis: sensitivity and inter observer agreement of (67)Ga imaging and (18)F-FDG PET. Q J Nucl Med Mol Imaging. 2011;55:66–71.PubMedGoogle Scholar
  64. 64.
    Teirstein AS, Judson MA, Baughman RP, et al. The spectrum of biopsy sites for the diagnosis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22:139–46.PubMedGoogle Scholar
  65. 65.
    Agarwal R, Aggarwal AN, Gupta D. Efficacy and safety of conventional TBNA in sarcoidosis: a systematic review and meta-analysis. Respir Care. 2013;58(4):683–93.PubMedGoogle Scholar
  66. 66.
    von Bartheld MB, Dekkers OM, Szlubowski A, et al. Endosonography vs conventional bronchoscopy for the diagnosis of sarcoidosis: the GRANULOMA randomized clinical trial. JAMA. 2013;309:2457–64.CrossRefGoogle Scholar
  67. 67.
    Costabel U, Bonella F, Ohshimo S, et al. Diagnostic modalities in sarcoidosis: BAL, EBUS, and PET. Semin Respir Crit Care Med. 2010;31:404–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Trisolini R, Lazzari Agli L, Cancellieri A, et al. The value of flexible transbronchial needle aspiration in the diagnosis of stage I sarcoidosis. Chest. 2003;124:2126–30.PubMedCrossRefGoogle Scholar
  69. 69.
    Shorr AF, Torrington KG, Hnatiuk OW. Endobronchial biopsy for sarcoidosis: a prospective study. Chest. 2001;120:109–14.PubMedCrossRefGoogle Scholar
  70. 70.
    Bilaceroglu S, Perim K, Gunel O, et al. Combining transbronchial aspiration with endobronchial and transbronchial biopsy in sarcoidosis. Monaldi Arch Chest Dis. 1999;54:217–23.PubMedGoogle Scholar
  71. 71.
    Plit M, Pearson R, Havryk A, et al. Diagnostic utility of endobronchial ultrasound-guided transbronchial needle aspiration compared with transbronchial and endobronchial biopsy for suspected sarcoidosis. Intern Med J. 2012;42:434–8.PubMedCrossRefGoogle Scholar
  72. 72.
    Nagai S, Izumi T. Bronchoalveolar lavage. Still useful in diagnosing sarcoidosis? Clin Chest Med. 1997;18:787–97.PubMedCrossRefGoogle Scholar
  73. 73.
    Meyer KC, Raghu G, Baughman RP, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;185:1004–14.PubMedCrossRefGoogle Scholar
  74. 74.
    Rosen Y, Vuletin JC, Pertschuk LP, et al. Sarcoidosis: from the pathologist’s vantage point. Pathol Annu. 1979;14(Pt 1):405–39.PubMedGoogle Scholar
  75. 75.
    Ohara K, Okubo A, Kamata K, et al. Transbronchial lung biopsy in the diagnosis of suspected ocular sarcoidosis. Arch Ophthalmol. 1993;111:642–4.PubMedCrossRefGoogle Scholar
  76. 76.
    Sartin JS, Walker RC. Granulomatous hepatitis: a retrospective review of 88 cases at the Mayo Clinic. Mayo Clin Proc. 1991;66:914–8.PubMedCrossRefGoogle Scholar
  77. 77.
    Morimoto Y, Routes JM. Granulomatous disease in common variable immunodeficiency. Curr Allergy Asthma Rep. 2005;5:370–5.PubMedCrossRefGoogle Scholar
  78. 78.
    Brincker H. Granulomatous lesions of unknown significance: the GLUS syndrome. In: James D, editor. Sarcoidosis and other granulomatous disorders. New York: Marcel Dekker; 1994. p. 69–76.Google Scholar
  79. 79.
    Judson MA. The diagnosis of sarcoidosis. Clin Chest Med. 2008;29:415–27. viii.PubMedCrossRefGoogle Scholar
  80. 80.
    Rose CD, Martin TM, Wouters CH. Blau syndrome revisited. Curr Opin Rheumatol. 2011;23:411–8.PubMedCrossRefGoogle Scholar
  81. 81.
    Wallaert B, Ramon P, Fournier EC, et al. Activated alveolar macrophage and lymphocyte alveolitis in extrathoracic sarcoidosis without radiological mediastinopulmonary involvement. Ann N Y Acad Sci. 1986;465:201–10.PubMedCrossRefGoogle Scholar
  82. 82.
    Baughman RP, Shipley R, Desai S, et al. Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest. 2009;136(2):526–35.PubMedGoogle Scholar
  83. 83.
    Bergin CJ, Bell DY, Coblentz CL, et al. Sarcoidosis: correlation of pulmonary parenchymal pattern at CT with results of pulmonary function tests. Radiology. 1989;171:619–24.PubMedGoogle Scholar
  84. 84.
    Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years’ observation. Br Med J. 1961;5261:1165–72.CrossRefGoogle Scholar
  85. 85.
    Baughman RP, Drent M, Culver DA, et al. Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29:90–8.PubMedGoogle Scholar
  86. 86.
    Lynch III JP, Ma YL, Koss MN, et al. Pulmonary sarcoidosis. Semin Respir Crit Care Med. 2007;28:53–74.PubMedCrossRefGoogle Scholar
  87. 87.
    Sharma OP, Johnson R. Airway obstruction in sarcoidosis. A study of 123 nonsmoking black American patients with sarcoidosis. Chest. 1988;94:343–6.PubMedCrossRefGoogle Scholar
  88. 88.
    Harrison BD, Shaylor JM, Stokes TC, et al. Airflow limitation in sarcoidosis—a study of pulmonary function in 107 patients with newly diagnosed disease. Respir Med. 1991;85:59–64.PubMedCrossRefGoogle Scholar
  89. 89.
    Shorr AF, Torrington KG, Hnatiuk OW. Endobronchial involvement and airway hyperreactivity in patients with sarcoidosis. Chest. 2001;120: 881–6.PubMedCrossRefGoogle Scholar
  90. 90.
    Mihailovic-Vucinic V, Zugic V, Videnovic-Ivanov J. New observations on pulmonary function changes in sarcoidosis. Curr Opin Pulm Med. 2003;9:436–41.PubMedCrossRefGoogle Scholar
  91. 91.
    Lynch III JP, Kazerooni EA, Gay SE. Pulmonary sarcoidosis. Clin Chest Med. 1997;18:755–85.PubMedCrossRefGoogle Scholar
  92. 92.
    Marcellis RG, Lenssen AF, Elfferich MD, et al. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J. 2011;38:628–34.PubMedCrossRefGoogle Scholar
  93. 93.
    Spruit MA, Thomeer MJ, Gosselink R, et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax. 2005;60:32–8.PubMedCentralPubMedCrossRefGoogle Scholar
  94. 94.
    Panselinas E, Halstead L, Schlosser RJ, et al. Clinical manifestations, radiographic findings, treatment options, and outcome in sarcoidosis patients with upper respiratory tract involvement. South Med J. 2010;103:870–5.PubMedCrossRefGoogle Scholar
  95. 95.
    Aubart FC, Ouayoun M, Brauner M, et al. Sinonasal involvement in sarcoidosis: a case–control study of 20 patients. Medicine (Baltimore). 2006;85:365–71.CrossRefGoogle Scholar
  96. 96.
    McCaffrey TV, McDonald TJ. Sarcoidosis of the nose and paranasal sinuses. Laryngoscope. 1983;93: 1281–4.PubMedGoogle Scholar
  97. 97.
    Yanardag H, Enoz M, Papila I, et al. Upper respiratory tract involvement of sarcoidosis in the Turkish population. Otolaryngol Head Neck Surg. 2006;134:848–51.PubMedCrossRefGoogle Scholar
  98. 98.
    Carasso B. Sarcoidosis of the larynx causing airway obstruction. Chest. 1974;65:693–5.PubMedCrossRefGoogle Scholar
  99. 99.
    Krespi YP, Mitrani M, Husain S, et al. Treatment of laryngeal sarcoidosis with intralesional steroid injection. Ann Otol Rhinol Laryngol. 1987;96:713–5.PubMedGoogle Scholar
  100. 100.
    Marks SC, Goodman RS. Surgical management of nasal and sinus sarcoidosis. Otolaryngol Head Neck Surg. 1998;118:856–8.PubMedCrossRefGoogle Scholar
  101. 101.
    Neville E, Mills RG, Jash DK, et al. Sarcoidosis of the upper respiratory tract and its association with lupus pernio. Thorax. 1976;31:660–4.PubMedCentralPubMedCrossRefGoogle Scholar
  102. 102.
    Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med. 1983;52:525–33.PubMedGoogle Scholar
  103. 103.
    Viskum K, Vestbo J. Vital prognosis in intrathoracic sarcoidosis with special reference to pulmonary function and radiological stage. Eur Respir J. 1993; 6:349–53.PubMedGoogle Scholar
  104. 104.
    Chambellan A, Turbie P, Nunes H, et al. Endoluminal stenosis of proximal bronchi in sarcoidosis: bronchoscopy, function, and evolution. Chest. 2005;127: 472–81.PubMedCrossRefGoogle Scholar
  105. 105.
    Udwadia ZF, Pilling JR, Jenkins PF, et al. Bronchoscopic and bronchographic findings in 12 patients with sarcoidosis and severe or progressive airways obstruction. Thorax. 1990;45:272–5.PubMedCentralPubMedCrossRefGoogle Scholar
  106. 106.
    Davies CW, Tasker AD, Padley SP, et al. Air trapping in sarcoidosis on computed tomography: correlation with lung function. Clin Radiol. 2000;55: 217–21.PubMedCrossRefGoogle Scholar
  107. 107.
    Lavergne F, Clerici C, Sadoun D, et al. Airway obstruction in bronchial sarcoidosis: outcome with treatment. Chest. 1999;116:1194–9.PubMedCrossRefGoogle Scholar
  108. 108.
    Polychronopoulos VS, Prakash UB. Airway involvement in sarcoidosis. Chest. 2009;136:1371–80.PubMedCrossRefGoogle Scholar
  109. 109.
    Battesti JP, Georges R, Basset F, et al. Chronic cor pulmonale in pulmonary sarcoidosis. Thorax. 1978;33:76–84.PubMedCentralPubMedCrossRefGoogle Scholar
  110. 110.
    Gluskowski J, Hawrylkiewicz I, Zych D, et al. Pulmonary haemodynamics at rest and during exercise in patients with sarcoidosis. Respiration. 1984;46:26–32.PubMedCrossRefGoogle Scholar
  111. 111.
    Preston IR, Klinger JR, Landzberg MJ, et al. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest. 2001;120:866–72.PubMedCrossRefGoogle Scholar
  112. 112.
    Shorr AF, Helman DL, Davies DB, et al. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J. 2005;25: 783–8.PubMedCrossRefGoogle Scholar
  113. 113.
    Emirgil C, Sobol BJ, Herbert WH, et al. The lesser circulation in pulmonary fibrosis secondary to sarcoidosis and its relationship to respiratory function. Chest. 1971;60:371–8.PubMedCrossRefGoogle Scholar
  114. 114.
    Baughman RP, Engel PJ, Taylor L, et al. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest. 2010;138:1078–85.PubMedCrossRefGoogle Scholar
  115. 115.
    Arcasoy SM, Christie JD, Pochettino A, et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest. 2001;120:873–80.PubMedCrossRefGoogle Scholar
  116. 116.
    Diaz-Guzman E, Farver C, Parambil J, et al. Pulmonary hypertension caused by sarcoidosis. Clin Chest Med. 2008;29:549–63.PubMedCentralPubMedCrossRefGoogle Scholar
  117. 117.
    Sulica R, Teirstein AS, Kakarla S, et al. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest. 2005;128:1483–9.PubMedCrossRefGoogle Scholar
  118. 118.
    Swigris JJ, Olson AL, Huie TJ, et al. Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007. Chest. 2011;140:1261–6.PubMedCentralPubMedCrossRefGoogle Scholar
  119. 119.
    Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J. 2008;32:296–302.PubMedCrossRefGoogle Scholar
  120. 120.
    Gluskowski J, Hawrylkiewicz I, Zych D, et al. Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis. Eur Respir J. 1990;3:403–7.PubMedGoogle Scholar
  121. 121.
    Baughman RP, Culver DA, Cordova FC, et al. Bosentan for sarcoidosis associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest. 2013 Oct 31. doi:  10.1378/chest.13-1766.
  122. 122.
    Baughman RP, Judson MA, Lower EE, et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26:110–20.PubMedGoogle Scholar
  123. 123.
    Barnett CF, Bonura EJ, Nathan SD, et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest. 2009;135:1455–61.PubMedCentralPubMedCrossRefGoogle Scholar
  124. 124.
    Soskel NT, Sharma OP. Pleural involvement in sarcoidosis. Curr Opin Pulm Med. 2000;6:455–68.PubMedCrossRefGoogle Scholar
  125. 125.
    De Vuyst P, De Troyer A, Yernault JC. Bloody pleural effusion in a patient with sarcoidosis. Chest. 1979;76:607–9.PubMedCrossRefGoogle Scholar
  126. 126.
    Aberg H, Bah M, Waters AW. Sarcoidosis: complicated by chylothorax. Minn Med. 1966;49:1065–70.PubMedGoogle Scholar
  127. 127.
    Poe RH. Middle-lobe atelectasis due to sarcoidosis with pleural effusion. N Y State J Med. 1978;78:2095–7.PubMedGoogle Scholar
  128. 128.
    Chusid EL, Siltzbach LE. Sarcoidosis of the pleura. Ann Intern Med. 1974;81:190–4.PubMedCrossRefGoogle Scholar
  129. 129.
    Beekman JF, Zimmet SM, Chun BK, et al. Spectrum of pleural involvement in sarcoidosis. Arch Intern Med. 1976;136:323–30.PubMedCrossRefGoogle Scholar
  130. 130.
    Huggins JT, Doelken P, Sahn SA, et al. Pleural effusions in a series of 181 outpatients with sarcoidosis. Chest. 2006;129:1599–604.PubMedCrossRefGoogle Scholar
  131. 131.
    Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29:119–27.PubMedGoogle Scholar
  132. 132.
    Johns CJ, Michele TM. The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital. Medicine (Baltimore). 1999;78: 65–111.CrossRefGoogle Scholar
  133. 133.
    Hours S, Nunes H, Kambouchner M, et al. Pulmonary cavitary sarcoidosis: clinico-radiologic characteristics and natural history of a rare form of sarcoidosis. Medicine (Baltimore). 2008;87:142–51.CrossRefGoogle Scholar
  134. 134.
    Jewkes J, Kay PH, Paneth M, et al. Pulmonary aspergilloma: analysis of prognosis in relation to haemoptysis and survey of treatment. Thorax. 1983;38:572–8.PubMedCentralPubMedCrossRefGoogle Scholar
  135. 135.
    Rockoff SD, Rohatgi PK. Unusual manifestations of thoracic sarcoidosis. AJR Am J Roentgenol. 1985;144:513–28.PubMedCrossRefGoogle Scholar
  136. 136.
    Rubinstein I, Baum GL, Rosenthal T. Fungal infections complicating pulmonary sarcoidosis. J Infect Dis. 1985;152:1360.PubMedCrossRefGoogle Scholar
  137. 137.
    Waldhorn RE, Tsou E, Kerwin DM. Invasive pulmonary aspergillosis associated with aspergilloma in sarcoidosis. South Med J. 1983;76:251–3.PubMedCrossRefGoogle Scholar
  138. 138.
    Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis. 2000;30:696–709.PubMedCrossRefGoogle Scholar
  139. 139.
    Jackson M, Flower CD, Shneerson JM. Treatment of symptomatic pulmonary aspergillomas with intracavitary instillation of amphotericin B through an indwelling catheter. Thorax. 1993;48:928–30.PubMedCentralPubMedCrossRefGoogle Scholar
  140. 140.
    Kravitz JN, Steed LL, Judson MA. Intracavitary voriconazole for the treatment of hemoptysis complicating Pseudallescheria angusta pulmonary mycetomas in fibrocystic sarcoidosis. Med Mycol. 2011;49:198–201.PubMedCrossRefGoogle Scholar
  141. 141.
    Dar MA, Ahmad M, Weinstein AJ, et al. Thoracic aspergillosis (Part I). Overview and aspergilloma. Cleve Clin Q. 1984;51:615–30.PubMedCrossRefGoogle Scholar
  142. 142.
    Crawshaw AP, Wotton CJ, Yeates DG, et al. Evidence for association between sarcoidosis and pulmonary embolism from 35-year record linkage study. Thorax. 2011;66:447–8.PubMedCrossRefGoogle Scholar
  143. 143.
    Perez RL, Duncan A, Hunter RL, et al. Elevated D dimer in the lungs and blood of patients with sarcoidosis. Chest. 1993;103:1100–6.PubMedCrossRefGoogle Scholar
  144. 144.
    Turner GA, Lower EE, Corser BC, et al. Sleep apnea in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1997;14:61–4.PubMedGoogle Scholar
  145. 145.
    Patterson KC, Huang F, Oldham JM, et al. Excessive daytime sleepiness and obstructive sleep apnea in patients with sarcoidosis. Chest. 2013;143:1562–8.PubMedCrossRefGoogle Scholar
  146. 146.
    de Kleijn WP, De Vries J, Lower EE, et al. Fatigue in sarcoidosis: a systematic review. Curr Opin Pulm Med. 2009;15(5):499–506.PubMedCrossRefGoogle Scholar
  147. 147.
    Chowdhury FU, Sheerin F, Bradley KM, et al. Sarcoid-like reaction to malignancy on whole-body integrated (18)F-FDG PET/CT: prevalence and disease pattern. Clin Radiol. 2009;64:675–81.PubMedCrossRefGoogle Scholar
  148. 148.
    Le Jeune I, Gribbin J, West J, et al. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med. 2007;101:2534–40.PubMedCrossRefGoogle Scholar
  149. 149.
    Brincker H, Wilbek E. The incidence of malignant tumours in patients with respiratory sarcoidosis. Br J Cancer. 1974;29:247–51.PubMedCentralPubMedCrossRefGoogle Scholar
  150. 150.
    Askling J, Grunewald J, Eklund A, et al. Increased risk for cancer following sarcoidosis. Am J Respir Crit Care Med. 1999;160:1668–72.PubMedCrossRefGoogle Scholar
  151. 151.
    Gribbin J, Hubbard RB, Le Jeune I, et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006;61:980–5.PubMedCentralPubMedCrossRefGoogle Scholar
  152. 152.
    Swigris JJ, Olson AL, Huie TJ, et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med. 2011;183:1524–30.PubMedCentralPubMedCrossRefGoogle Scholar
  153. 153.
    Sekiguchi M, Yazaki Y, Isobe M, et al. Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations. Cardiovasc Drugs Ther. 1996;10:495–510.PubMedCrossRefGoogle Scholar
  154. 154.
    Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357:2153–65.PubMedCrossRefGoogle Scholar
  155. 155.
    Nagai S, Shigematsu M, Hamada K, et al. Clinical courses and prognoses of pulmonary sarcoidosis. Curr Opin Pulm Med. 1999;5:293–8.PubMedCrossRefGoogle Scholar
  156. 156.
    Judson MA, Baughman RP, Thompson BW, et al. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:204–11.PubMedGoogle Scholar
  157. 157.
    Chappell AG, Cheung WY, Hutchings HA. Sarcoidosis: a long-term follow up study. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17:167–73.PubMedGoogle Scholar
  158. 158.
    Mana J, Salazar A, Manresa F. Clinical factors predicting persistence of activity in sarcoidosis: a multivariate analysis of 193 cases. Respiration. 1994;61:219–25.PubMedCrossRefGoogle Scholar
  159. 159.
    Baughman RP, Judson MA, Teirstein A, et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM. 2006;99:307–15.PubMedCrossRefGoogle Scholar
  160. 160.
    Baughman RP, Nagai S, Balter M, et al. Defining the clinical outcome status (COS) in sarcoidosis: results of the WASOG task force. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28:56–64.PubMedGoogle Scholar
  161. 161.
    Akira M, Kozuka T, Inoue Y, et al. Long-term follow-up CT scan evaluation in patients with pulmonary sarcoidosis. Chest. 2005;127:185–91.PubMedCrossRefGoogle Scholar
  162. 162.
    Baughman RP, Winget DB, Bowen EH, et al. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 1997;14:154–8.PubMedGoogle Scholar
  163. 163.
    Brauner MW, Lenoir S, Grenier P, et al. Pulmonary sarcoidosis: CT assessment of lesion reversibility. Radiology. 1992;182:349–54.PubMedGoogle Scholar
  164. 164.
    Lazar CA, Culver DA. Treatment of sarcoidosis. Semin Respir Crit Care Med. 2010;31:501–18.PubMedCrossRefGoogle Scholar
  165. 165.
    Hunninghake GW, Gilbert S, Pueringer R, et al. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med. 1994;149:893–8.PubMedCrossRefGoogle Scholar
  166. 166.
    Grunewald J, Eklund A. Lofgren’s syndrome: human leukocyte antigen strongly influence the disease course. Am J Respir Crit Care Med. 2009;179(4):307–12.PubMedCrossRefGoogle Scholar
  167. 167.
    Gottlieb JE, Israel HL, Steiner RM, et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest. 1997;111:623–31.PubMedCrossRefGoogle Scholar
  168. 168.
    Alberts C, van der Mark TW, Jansen HM. Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Dutch Study Group on Pulmonary Sarcoidosis. Eur Respir J. 1995;8: 682–8.PubMedGoogle Scholar
  169. 169.
    Erkkila S, Froseth B, Hellstrom PE, et al. Inhaled budesonide influences cellular and biochemical abnormalities in pulmonary sarcoidosis. Sarcoidosis. 1988;5:106–10.PubMedGoogle Scholar
  170. 170.
    Milman N, Graudal N, Grode G, et al. No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study. J Intern Med. 1994;236:285–90.PubMedCrossRefGoogle Scholar
  171. 171.
    Zych D, Pawlicka L, Zielinski J. Inhaled budesonide vs prednisone in the maintenance treatment of pulmonary sarcoidosis. Sarcoidosis. 1993;10:56–61.PubMedGoogle Scholar
  172. 172.
    du Bois RM, Greenhalgh PM, Southcott AM, et al. Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study. Eur Respir J. 1999;13:1345–50.PubMedCrossRefGoogle Scholar
  173. 173.
    Baughman RP, Iannuzzi MC, Lower EE, et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19:198–204.PubMedGoogle Scholar
  174. 174.
    Johns CJ, Schonfeld SA, Scott PP, et al. Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroid therapy. Outcome and complications. Ann N Y Acad Sci. 1986;465:702–12.PubMedCrossRefGoogle Scholar
  175. 175.
    Sweiss N, Yeager H. Sarcoidosis requiring systemic treatment: why not a steroid-sparing regimen up-front? Sarcoidosis Vasc Diffuse Lung Dis. 2010;27: 3–4.PubMedGoogle Scholar
  176. 176.
    Judson MA. An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest. 1999;115:1158–65.PubMedCrossRefGoogle Scholar
  177. 177.
    Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev. 2005:CD001114.Google Scholar
  178. 178.
    Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a delphi consensus study. Respir Med. 2010;104(5): 717–23.PubMedCrossRefGoogle Scholar
  179. 179.
    Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA. 2002;287:1301–7.PubMedCrossRefGoogle Scholar
  180. 180.
    Cox CE, Donohue JF, Brown CD, et al. Health-related quality of life of persons with sarcoidosis. Chest. 2004;125:997–1004.PubMedCrossRefGoogle Scholar
  181. 181.
    Sharma OP. Pulmonary sarcoidosis and corticosteroids. Am Rev Respir Dis. 1993;147:1598–600.PubMedCrossRefGoogle Scholar
  182. 182.
    Winterbauer RH, Kirtland SH, Corley DE. Treatment with corticosteroids. Clin Chest Med. 1997;18:843–51.PubMedCrossRefGoogle Scholar
  183. 183.
    Goldstein DS, Williams MH. Rate of improvement of pulmonary function in sarcoidosis during treatment with corticosteroids. Thorax. 1986;41:473–4.PubMedCentralPubMedCrossRefGoogle Scholar
  184. 184.
    Siltzbach LE. Effects of cortisone in sarcoidosis; a study of thirteen patients. Am J Med. 1952;12: 139–60.PubMedCrossRefGoogle Scholar
  185. 185.
    Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17:60–6.PubMedGoogle Scholar
  186. 186.
    Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax. 1996;51: 238–47.PubMedCentralPubMedCrossRefGoogle Scholar
  187. 187.
    Vorselaars AD, Wuyts WA, Vorselaars VM, et al. Methotrexate versus azathioprine in second line therapy of sarcoidosis. Chest. 2013;144(3):805–12.PubMedCrossRefGoogle Scholar
  188. 188.
    Baughman RP, Lower EE. A clinical approach to the use of methotrexate for sarcoidosis. Thorax. 1999; 54:742–6.PubMedCentralPubMedCrossRefGoogle Scholar
  189. 189.
    Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med. 1995;155:846–51.PubMedCrossRefGoogle Scholar
  190. 190.
    Webster GF, Razsi LK, Sanchez M, et al. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol. 1991;24:451–4.PubMedCrossRefGoogle Scholar
  191. 191.
    Cremers JP, Drent M, Bast A, et al. Multinational evidence-based World Association of Sarcoidosis and other granulomatous disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med. 2013;19:545–61.PubMedCrossRefGoogle Scholar
  192. 192.
    Sahoo DH, Bandyopadhyay D, Xu M, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J. 2011;38:1145–50.PubMedCrossRefGoogle Scholar
  193. 193.
    Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21:43–8.PubMedGoogle Scholar
  194. 194.
    Baltzan M, Mehta S, Kirkham TH, et al. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med. 1999;160:192–7.PubMedCrossRefGoogle Scholar
  195. 195.
    Kindler V, Sappino AP, Grau GE, et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell. 1989;56:731–40.PubMedCrossRefGoogle Scholar
  196. 196.
    Marino MW, Dunn A, Grail D, et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci U S A. 1997;94:8093–8.PubMedCentralPubMedCrossRefGoogle Scholar
  197. 197.
    Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174:795–802.PubMedCrossRefGoogle Scholar
  198. 198.
    Erckens RJ, Mostard RL, Wijnen PA, et al. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012;250:713–20.PubMedCentralPubMedCrossRefGoogle Scholar
  199. 199.
    Kamphuis LS, Lam-Tse WK, Dik WA, et al. Efficacy of adalimumab in chronically active and symptomatic patients with sarcoidosis. Am J Respir Crit Care Med. 2011;184:1214–6.PubMedCrossRefGoogle Scholar
  200. 200.
    Milman N, Graudal N, Loft A, et al. Effect of the TNF-alpha inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET. Clin Respir J. 2012;6(4): 238–47.PubMedCrossRefGoogle Scholar
  201. 201.
    Nathan SD. Lung transplantation: disease-specific considerations for referral. Chest. 2005;127: 1006–16.PubMedCrossRefGoogle Scholar
  202. 202.
    Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant. 2012;31:1073–86.PubMedCrossRefGoogle Scholar
  203. 203.
    Shorr AF, Helman DL, Davies DB, et al. Sarcoidosis, race, and short-term outcomes following lung transplantation. Chest. 2004;125:990–6.PubMedCrossRefGoogle Scholar
  204. 204.
    Nunley DR, Hattler B, Keenan RJ, et al. Lung transplantation for end-stage pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16: 93–100.PubMedGoogle Scholar
  205. 205.
    Milman N, Burton C, Andersen CB, et al. Lung transplantation for end-stage pulmonary sarcoidosis: outcome in a series of seven consecutive patients. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22:222–8.PubMedGoogle Scholar
  206. 206.
    Ionescu DN, Hunt JL, Lomago D, et al. Recurrent sarcoidosis in lung transplant allografts: granulomas are of recipient origin. Diagn Mol Pathol. 2005;14: 140–5.PubMedCrossRefGoogle Scholar
  207. 207.
    Padilla ML, Schilero GJ, Teirstein AS. Sarcoidosis and transplantation. Sarcoidosis Vasc Diffuse Lung Dis. 1997;14:16–22.PubMedGoogle Scholar
  208. 208.
    Johnson BA, Duncan SR, Ohori NP, et al. Recurrence of sarcoidosis in pulmonary allograft recipients. Am Rev Respir Dis. 1993;148:1373–7.PubMedCrossRefGoogle Scholar
  209. 209.
    Heatly T, Sekela M, Berger R. Single lung transplantation involving a donor with documented pulmonary sarcoidosis. J Heart Lung Transplant. 1994;13:720–3.PubMedGoogle Scholar
  210. 210.
    Burke RR, Rybicki BA, Rao DS. Calcium and vitamin D in sarcoidosis: how to assess and manage. Semin Respir Crit Care Med. 2010;31:474–84.PubMedCrossRefGoogle Scholar
  211. 211.
    James DG, Neville E, Siltzbach LE. A worldwide review of sarcoidosis. Ann N Y Acad Sci. 1976;278:321–34.PubMedCrossRefGoogle Scholar
  212. 212.
    Muther RS, McCarron DA, Bennett WM. Renal manifestations of sarcoidosis. Arch Intern Med. 1981;141:643–5.PubMedCrossRefGoogle Scholar
  213. 213.
    Rizzato G, Fraioli P. Natural and corticosteroid-induced osteoporosis in sarcoidosis: prevention, treatment, follow up and reversibility. Sarcoidosis. 1990;7:89–92.PubMedGoogle Scholar
  214. 214.
    Stoffels K, Overbergh L, Giulietti A, et al. Immune regulation of 25-hydroxyvitamin-D3-1alpha-hydroxylase in human monocytes. J Bone Miner Res. 2006;21:37–47.PubMedCrossRefGoogle Scholar
  215. 215.
    Sweiss NJ, Lower EE, Korsten P, et al. Bone health issues in sarcoidosis. Curr Rheumatol Rep. 2011;13: 265–72.PubMedCentralPubMedCrossRefGoogle Scholar
  216. 216.
    Gonnelli S, Rottoli P, Cepollaro C, et al. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int. 1997;61:382–5.PubMedCrossRefGoogle Scholar
  217. 217.
    FRAX. WHO Fracture Risk Assessment Tool, 2013.Google Scholar
  218. 218.
    Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62:1515–26.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Respiratory Institute, Cleveland ClinicClevelandUSA

Personalised recommendations